Who are eltrombopag combining rituximab's main competitors?

No direct comparators detected in our index.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/eltrombopag-combining-rituximab.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

eltrombopag combining rituximab — Competitive Intelligence Brief

eltrombopag combining rituximab (eltrombopag combining rituximab) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Combination therapy: thrombopoietin receptor agonist + monoclonal antibody. Area: Hematology/Immunology.

marketed Combination therapy: thrombopoietin receptor agonist + monoclonal antibody TPO receptor (c-Mpl) and CD20 Hematology/Immunology Small molecule Live · refreshed every 30 min

Target snapshot

eltrombopag combining rituximab (eltrombopag combining rituximab) — Institute of Hematology & Blood Diseases Hospital, China. Eltrombopag and rituximab together work to increase platelet production while depleting B cells to treat immune thrombocytopenia.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
eltrombopag combining rituximab TARGET	eltrombopag combining rituximab	Institute of Hematology & Blood Diseases Hospital, China	marketed	Combination therapy: thrombopoietin receptor agonist + monoclonal antibody	TPO receptor (c-Mpl) and CD20

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Combination therapy: thrombopoietin receptor agonist + monoclonal antibody class)

Institute of Hematology & Blood Diseases Hospital, China · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). eltrombopag combining rituximab — Competitive Intelligence Brief. https://druglandscape.com/ci/eltrombopag-combining-rituximab. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab